CNBC 快讯 10月2日 15:20 礼来与诺和诺德押注胰淀素：GLP-1 之后的下一代减肥药管线争夺战 Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity an… FG 100 读报告 →